Harbour Investments’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$48 Hold
15
﹤0.01% 4582
2025
Q4
$65 Hold
15
﹤0.01% 3771
2025
Q3
$585 Buy
15
+1
+7% +$28 ﹤0.01% 3490
2025
Q2
$327 Hold
14
﹤0.01% 3427
2025
Q1
$213 Buy
+14
New +$211 ﹤0.01% 3427
2024
Q4
Sell
-15
Closed -$162 3597
2024
Q3
$162 Hold
15
﹤0.01% 3289
2024
Q2
$135 Hold
15
﹤0.01% 3190
2024
Q1
$478 Buy
15
+6
+67% +$156 ﹤0.01% 3028
2023
Q4
$237 Hold
9
﹤0.01% 3003
2023
Q3
$536 Buy
9
+2
+29% +$188 ﹤0.01% 2797
2023
Q2
$708 Hold
7
﹤0.01% 2756
2023
Q1
$1.23K Hold
7
﹤0.01% 2653
2022
Q4
$2.69K Hold
7
﹤0.01% 2443
2022
Q3
$2K Hold
7
﹤0.01% 2501
2022
Q2
$2K Buy
+7
New +$2.46K ﹤0.01% 2501
2021
Q4
$3K Sell
7
-62
-90% -$31.2K ﹤0.01% 2354
2021
Q3
$38K Sell
69
-7
-9% -$3.51K ﹤0.01% 1946
2021
Q2
$39K Buy
76
+1
+1% +$634 ﹤0.01% 1958
2021
Q1
$59K Buy
+75
New +$51.3K ﹤0.01% 1600

Other funds holding TVRD

Harbour Investments's TVRD Position: Q1 2026 in Review

Harbour Investments held its Tvardi Therapeutics (TVRD) position steady in Q1 2026 at 15 shares worth $48. The position accounts for ﹤0.01% of the portfolio, ranked #4582.

Harbour Investments first reported a position in TVRD in Q1 2021 and has held it in 19 quarters since. The position peaked at $59K in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Harbour Investments held 15 shares of Tvardi Therapeutics worth $48 as of Q1 2026.
  • Harbour Investments left its Tvardi Therapeutics share count unchanged in Q1 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4582 holding.
  • Harbour Investments first reported a position in Tvardi Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • Harbour Investments's Tvardi Therapeutics position peaked at $59K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.